OVERLORD-MS
What was tested
Treatment tested
- Rituximab
B-lymphocyte antigen CD20 binding agent
Compared with
- Ocrelizumab
B-lymphocyte antigen CD20 binding agent
What it measured
Main measures
The primary endpoint is to determine the difference in efficacy and safety between rituximab and ocrelizumab according to the following criteria:
Safety
Other measures (1)
•Proportion of patients with 6-months confirmed disability progression (6M-CDP) as measured by the Expanded disability status scale (EDSS) from baseline to month 24. CDP-EDSS defined as an increase of one point in the EDSS score confirmed after 6 months, with an absence of relapse at the time of assessment.
Disability progressionRelapses
Papers
Results
Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.N Engl J Med · 2026
Loading reviews and guidelines…
Related trials
- Operetta III
Phase 2 · Not yet recruiting
Still running
- SOLI
Recruiting
Still running
- SONATA-MS
Recruiting
Still running
- HiHat
Phase 2 · Recruiting
Still running
- REDIFINE MS
Recruiting
Still running
- TG1101-RMS-PED304
Phase 2 / Phase 3 · Recruiting
Still running
History
- In scope changed from true to false
Started
Jun 2020
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error